Research Briefs: Gore Iliac Branch Trial; Svelte DES Trial; TherOx SSO2 Data
This article was originally published in The Gray Sheet
Gore is sponsoring a 60-patient trial of its Excluder iliac branch endoprosthesis. Svelte’s randomized DIRECT II trial of its sirolimus-eluting stent has finished enrollment, and TherOx has positive data on its second-generation SSO2 system for reducing the size of myocardial infarcts.
You may also be interested in...
When it comes to treating acute heart attack patients, primary percutaneous coronary intervention (PPCI) remains the gold standard of care. And while this life-saving procedure restores blood flow through the coronary artery, perfusion in all areas of the heart may not occur. In this article, we'll highlight three innovative medtech companies that have developed very different solutions to try to improve upon the current standard of care and hear perspectives from interventional cardiologists.
Research news on hip replacements, a spinal cord stimulator and more.
In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.